[A multicenter, randomized, double-blind, placebo-controlled safety study to evaluate the clinical effects and quality of life of paclitaxel-carboplatin (PC) alone or combined with endostar for advanced non-small cell lung cancer (NSCLC)].
Baohui Han(Shanghai Jiao Tong University), Xianqiao Jin, Shuliang Guo(Apple (Israel)), Jianying Zhou(First Affiliated Hospital Zhejiang University), Liyan Jiang(Southwest University), Zhixiang Zhuang(Soochow University), Chunlei Shi(Shanghai Jiao Tong University), Yi Luo(Guangzhou University of Chinese Medicine), Chunxue Bai(Fudan University), Yang Zhang(Guangdong Testing Institute for Product Quality Supervision), Wenchao Liu, Jie Shen(Xinjiang Medical University), Bo Jin, Aiqin Gu(Nantong University), Qingyu Xiu(Second Military Medical University), Huimin Wang(Jilin University)
PubMed
November 1, 2011
Cited by 15
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study
|The Lancet|2018|1.7k